Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) EBIT: 2018-2024

Historic EBIT for Eton Pharmaceuticals (ETON) over the last 7 years, with Dec 2024 value amounting to -$2.6 million.

  • Eton Pharmaceuticals' EBIT fell 367.78% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year increase of 48.67%. This contributed to the annual value of -$2.6 million for FY2024, which is 117.87% down from last year.
  • Latest data reveals that Eton Pharmaceuticals reported EBIT of -$2.6 million as of FY2024, which was down 117.87% from -$1.2 million recorded in FY2023.
  • Eton Pharmaceuticals' 5-year EBIT high stood at -$1.2 million for FY2023, and its period low was -$27.1 million during FY2020.
  • Moreover, its 3-year median value for EBIT was -$2.6 million (2024), whereas its average is -$4.0 million.
  • Its EBIT has fluctuated over the past 5 years, first soared by 94.49% in 2021, then plummeted by 452.51% in 2022.
  • Over the past 5 years, Eton Pharmaceuticals' EBIT (Yearly) stood at -$27.1 million in 2020, then surged by 94.49% to -$1.5 million in 2021, then slumped by 452.51% to -$8.3 million in 2022, then skyrocketed by 85.57% to -$1.2 million in 2023, then plummeted by 117.87% to -$2.6 million in 2024.